NCT04808908View on ClinicalTrials.gov

Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

July 18, 2022

Study Completion Date

January 1, 2023

Conditions
HivHIV InfectionsAIDS
Interventions
BIOLOGICAL

N-803

N-803, provided by ImmunityBio., Inc. will be administered subcutaneously at a dose 6 mcg/kg on Days 0, 21, and 42 (with a dosing window of up to 14 days post the planned dosing day)

Trial Locations (2)

55415

Hennepin County Medical Center, Minneapolis

55455

University of Minnesota, Minneapolis

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Minnesota

OTHER

NCT04808908 - Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease | Biotech Hunter | Biotech Hunter